Variation in use of targeted therapies for metastatic renal cell carcinoma: Results from a Dutch population-based registry

BACKGROUND: For patients with metastatic renal cell carcinoma (mRCC), targeted therapies have entered the market since 2006. The aims of this study were to evaluate the uptake and use of targeted therapies for mRCC in The Netherlands, examine factors associated with the prescription of targeted ther...

Descripción completa

Detalles Bibliográficos
Autores principales: De Groot, S., Sleijfer, S., Redekop, W. K., Oosterwijk, E., Haanen, J. B. A. G., Kiemeney, L. A. L. M., Uyl-de Groot, C. A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4902930/
https://www.ncbi.nlm.nih.gov/pubmed/27286871
http://dx.doi.org/10.1186/s12885-016-2395-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4902930/
https://www.ncbi.nlm.nih.gov/pubmed/27286871
http://dx.doi.org/10.1186/s12885-016-2395-x

Ejemplares similares